8 Abstract Polyomavirus BK latently persist in different 9 sites, including the renourinary tract, and may reactivate 10 causing nephropathy in renal transplant recipients or 11 hemorrhagic cystitis in bone marrow recipients. Based on 12 the sequence of the VP1 gene, four genotypes have been 13 described, corresponding to the four serologically differ-14 entiated subtypes I-IV, with different prevalence and 15 geographic distribution. In this study, the development and 16 clinical validation of four different Real-Time PCR assays 17 for the detection and discrimination of BKV genotypes as a 18 substitute of DNA sequencing are described. 379 BK VP1 19 sequences, belonging to the main four genotypes, were 20 aligned and ''hot spots'' of mutation specific for all the 21 strains or isolates were identified. Specific primers and 22 probes for the detection and discrimination of each geno-23 type by four Real-Time PCR assays were designed and 24 technically validated. Subsequently, the four Real-Time 25 PCR assays were used to test 20 BK-positive urine speci-26 mens from renal transplant patients, and evidenced a 27 prevalence of BK genotype I, as previously reported in 28 Europe. Results were confirmed by sequencing. The 29 availability of a rapid and simple genotyping method could 30 be useful for the evaluation of BK genotypes prevalence 31 and studies on the impact of the infecting genotype on viral 32 biological behavior, pathogenic role, and immune evasion 33 strategies.
Introduction

38
BK virus (BKV) belongs to the Polyomaviridae family and 39 has a circular double-stranded DNA genome of about 40 5100 bp [1] . After primary infection that usually occurs in 41 the childhood and, which is mainly asymptomatic, BKV 42 remains latent at different sites, including the renourinary 43 tract, B-cells, and brain [2] . Reactivation with viruria may 44 occur, mainly in the context of immunosuppression, and 45 potentially lead to nephropathy (BKV-associated nephrop-46 athy-BKVAN) in renal transplant recipients [3] or hem-47 orrhagic cystitis in bone marrow transplant patients [4] . 48 BKV is the only primate polyomavirus with serologi-49 cally differentiated subtypes (I-IV) [5] . Jin and colleagues 50 developed a genotyping method based on the amplification 51 of the epitope region of the VP1 gene by polymerase chain 52 reaction (PCR) and classified viral isolates in four different
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53 genotypes (BKV I-IV) corresponding to the serological 54 ones [6] .
55
The geographical distribution of BKV subtypes has been 56 investigated in different studies [7] [8] [9] [10] , evidencing a higher 57 prevalence for BKV I worldwide and a minor but consis-58 tent occurrence of BKV IV, in particular in South-East 59 Asia. On the other hand, the prevalence of BKV II and 60 BKV III is very low with a higher presence of BKV III in 61 the African continent. This genotyping method is based on 62 the presence of single nucleotide polymorphisms (SNPs) 63 conserved between the various isolates belonging to each 64 of the four genotypes. Many different biomolecular pro-65 cedures have been developed to detect and discriminate 66 SNPs [11] [12] [13] [14] ; among these, the ARMS PCR [15] uses the 67 discriminatory power of the terminal 3 0 nucleotide to obtain 68 a successful amplification only for the DNA strand with a 69 correct complementariness.
70
In this article, we describe the design of four different 71 Real-Time PCR assays which can detect and discriminate 72 among the four main BKV genotypes (I-IV) as a valid 73 substitute of DNA sequencing.
Materials and Methods
BKV Sequences and Phylogenetic Analyses
76 379 BKV VP1 sequences, belonging to the main four 77 genotypes (I-IV), were obtained from three different arti-78 cles [8-10] by extrapolation from the server Nucleotide 79 (www.ncbi.nlm.nih.gov/nucleotide/). Nucleotide positions 80 from 1663 to 1912 (Dunlop strain complete genome, 81 GeneBank Access no. V01108) were considered to obtain 82 250-bp length DNA sequences. Subsequently, the VP1 83 DNA sequences were aligned using the software Clustal X 84 (i.e., the graphical version, with windows interface, of the 85 bioinformatic software Clustal W). This software, that 86 incorporates a novel position-specific scoring scheme and a 87 weighting scheme for down weighting over-represented 88 sequence groups, is used for multiple sequence alignment 89 and phylogenetic analysis, with the possibility to draw 90 phylogenetic trees. The software BioEdit was used to 91 manipulate the alignment for a clearer sight of differences 92 between the aligned sequences. BioEdit software is a user-93 friendly tool for post-alignment modifications, with the 94 possibility to emphasize few sequences, cut and paste 95 them, and make other evaluations, such as restriction 96 mapping. The BKV VP1 sequences were then used for 97 Phylogenetic analyses. Clustal X, that was utilized to make 98 a neighbor-joining phylogenetic tree, and the free software 99 NJplot were employed to display the resulting tree. The 100 confidence of branching patterns of the neighbor-joining 101 tree was determined by bootstrap analysis, using a set of 102 1,000 replicates.
103
Primers and Probes Design
104
The alignment was screened to find ''hot spots'' of muta-105 tion specific for all the strains or isolates belonging to each 106 genotype ( Fig. 1 ). In the absence of a specific single 107 nucleotide mutation, the occurrence of a different nucleo-108 tide combination between the genotypes was considered.
109 Every mutation was evaluated as a possible target for 110 designing of a set of primers able to recognize all the BKV 111 strains belonging to a specific genotype and to discriminate 112 between the others by a mismatch at the 3 0 primer ending. 113 The parameters that were taken into consideration for 114 selecting the ''hot spots'' and discriminating the primers 115 design were the presence of a unique sequence shared 116 between the strains belonging to one genotype but not to 117 the others, the 60°C melting temperature, and the possi-118 bility to design a Real-Time PCR probe in the most con-119 served nucleotide region inside the hypothetic amplicon. 120 Primers and probes were designed with the help of the 121 software Primer Express Ò v3.0 (Applied Biosystem, 122 Cheshire, UK). The primers obtained were then analyzed 123 with the Autodimer Software, an open-source tool that 124 evaluates the hairpin and primer-dimer formation, with the 125 aim of excluding the presence of factors that could alter the 126 amplification efficiency. In order to include all the strains 151 The following thermal profile was used: one cycle of 152 decontamination at 50°C for 2 min, one cycle of denatur-153 ation at 95°C for 10 min, and followed by 45 cycles of 154 amplification at: 95°C for 15 s, and 60°C for 60 s. The 155 following parameters were considered for the evaluation: 156 quick observation of the amplification, and good discrim-157 ination between the specific and aspecific amplification.
158
Plasmids and Standards
159
The BKV I Dunlop standard plasmid was kindly provided 160 by Prof. Tiziana Musso. The BKV II and BKV III standard 161 plasmids were produced starting from the ultramers (Tema 162 Ricerca), then amplified with cloning primers (Table 1) .
163 The BKV IV standard plasmid was prepared starting from 164 the BKV IV isolate J/2296/04 (kindly provided by Dr. Andi 165 Krumbholz). The primers were used for producing a PCR 166 product, then cloned using the pTOPO-TA cloning system 167 (Invitrogen) and propagated in competent Escherichia coli 168 TOP10 cells. After overnight culture, selected transformed 169 clones were amplified by culture in liquid LB medium 170 (10 g BACTOTRYPTONE, 5 g yeast extract, 171 mM 171 NaCl, and 15 g/l agar, pH 7.5) containing 50 lg/ml of 172 ampicillin. Plasmid DNA was extracted and purified using 173 the Wizard Plus SV Miniprep DNA Purification System 174 (Promega, Madison, WI). The plasmid concentration was 175 estimated on spectrophotometric reading at OD260. 178 The four genotyping assays were evaluated using serial 179 10-fold dilutions of the target plasmid (ranging from 10 7 to 180 10 copies per reaction). The linearity was assessed by the 181 correlation coefficient (R 2 ) of the standard curve obtained by 182 plotting 10 7 -10 standard copies per reaction with the four 183 different tests. The efficiency was evaluated by the slope of 184 the standard curve, using the formula E = 10 (-1/slope) -1.
185
In order to discriminate between specific and aspecific 186 amplifications, three repetitions of 10 [17] .
198
The limit of detection, defined as the lowest target 199 quantity detectable, was also estimated by serial 10-fold 200 standard dilutions. The precision of each test was calcu-201 lated by the intra-and inter-test coefficients of variation, 202 according to the formula CV = 100•(r/MC), where MC is 203 the average measured concentration, and r the correspon-204 dent standard deviation. Three repetitions for each standard 205 dilution were considered in the same run or in different 206 experiments, for the intra-and the inter-assay coefficients 207 of variation, respectively.
Clinical Specimens
209 Twenty urine specimens resulting positive to a reference 210 amplification assay (BKV Q-PCR Alert Kit [Nanogen, 211 Buttigliera Alta, Turin, Italy]) were tested with the four 212 amplification assays to assess the genotyping procedure. 213 Automated DNA extraction was performed with the 214 NucliSens EasyMAG platform (bioMeriéux, Marcy l'Eto-215 ile, France) from 1 ml of urine, according to the manu-216 facturer's instructions, and eluted to a final volume of 217 50 ll. Five microliters of extracted specimen were then 218 added to 15 ll of each genotyping mix. The results were 219 analyzed using the System SDS software. 
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273 gap of approximately 14.8-14.68 Ct s separated the specific 274 and aspecific amplifications; moreover, no aspecific ampli-275 fication was evidenced for lower dilution. 276 BKV II genotype mix that resulted was able to amplify 277 the specific BKV II target sequence;' however, this was 278 also amplified by the other three BKV discriminating 279 mixes. Only the amplification of the BKV II-specific target 280 with the corresponding mix was linear, and the threshold 281 crossing appeared at least 15 cycles earlier for BKV II mix 282 at 10 7 copies/reaction compared to the other amplification 283 mixes, decreasing to six cycles at 10 3 copies/reaction. The 284 amplification with BKV II mix at lower BKV II genotype-285 specific target concentration was considered not discrimi-286 nating, because of the overlapping Ct with BKV III and IV 287 amplification mixes. The BKV III target was recognized by 288 the corresponding mix with a linear amplification; how-289 ever, 10 7 copies/reaction were recognized also by the BKV 290 I mix, although a mean gap of 17.84 Ct s was observed 291 between specific and aspecific amplifications. An undis-292 tinguishable specific amplification was seen with a con-293 centration of BKV III of 10 copies/reaction, because of the 294 simultaneous amplification with BKV II, III, and IV mixes 295 with a similar Ct. The BKV IV target showed a specific 296 recognition using the corresponding mix, although the 297 target was also amplified with BKV II and III mixes at 10 7 298 copies/reaction, with a mean gap of 18.21 and 18.45 Ct s 299 between specific and aspecific amplifications for BKV II 300 and III mixes, respectively. However, at a concentration of 301 10 3 copies/reaction, the target was also recognized by BKV 302 I mix with a mean gap of 4.48 mean Ct s . 303 Using the same data to evaluate the specific and aspe-304 cific amplifications, a Ct lim was calculated for each geno-305 typing amplification, as an interference limit (Table 3 ). The 306 precision was calculated with the intra-and inter-test 307 coefficients of variation (Table 4) . 308 In order to establish the limit of detection for the four dif-309 ferent genotyping amplifications, 10-fold dilutions of the 310 targets (ranging from 10 7 to 10 copies/reaction) were ampli-311 fied with the above four methods. The limit of detection dif-312 fered between the four genotyping amplification procedures 313 and was as follows: 10 2 copies/reaction for BKV IV and 10 314 copies/reaction for BKV I, II, and III, each. However, only 315 BKV III procedure showed a sensitivity of 10 copies/reaction, 316 while for the others assay, it was of 100 copies/reaction. 317 Results for the clinical specimens are reported in Table 5 . 318 In brief, the amplification procedures yielded positive results In most of the cases, the viral load found with the devel-326 oped methods differed from that obtained with the reference 327 method, with a percentage of variation ranging from -288.4 328 to 89.9% (Table 5) . Furthermore, more aspecific amplifica-329 tions were observed in clinical specimens. In fact, the sample 330 #2998 showed two aspecific plots (BKV I and BKV II), while 331 no BKV I amplification was observed with a 10 7 copies/ 332 reaction plasmid dilution. Nevertheless, the occurrence of 333 aspecific amplifications did not impact on the genotyping 334 performance of the Real-Time PCRs, as the gap between the 335 curves of amplifications remained wide.
Discussion
337
In this study, a Real-Time PCR-based method for geno-338 typing of polyomavirus BK was developed. By 339 hemagglutination inhibition tests, four main BKV sero-340 types were described [5] , based on the differences in a short 341 amino acidic sequence on VP1 protein, probably being 342 responsible for the serotypical differences among BKV 343 variants [18] . Correspondingly, four main BKV VP1 344 genotypes were found, and their nucleotide sequences 345 analyzed [18] . 364 However, in this study, we chose to use the VP1 region 365 instead of LTA as we aimed to produce powerful dis-366 criminating Real-Time PCRs taking into consideration the 367 data published in the literature. Indeed, a higher number of 368 sequences is banked in public domain servers for VP1 369 compared to LTA, thus permitting a more detailed primers-370 and-probes design for the detection of a higher number of 371 sequences and corresponding polymorphic residues. In this 372 study, four Real-Time PCR assays, each one that can 373 amplify specifically a specific genotype, were designed, 374 and four different amplification mixes were produced to 375 avoid a too high concentration of primers in a single well, 376 that could determine dimer formation or an increase in the 377 aspecific performance. In fact, in the presence of high viral 378 loads, aspecific amplifications might appear, and these 379 were detectable as a low quantity amplification with other 380 genotype mixes; anyway, the aspecific amplification was 381 easily recognizable by the wide gap between the specific 382 and aspecific plots. Moreover, the introduction of Ct lim and 383 interference limit gave further clues about discrimination.
384 Clearer results were available for 10 7 -10 5 copies/reaction 385 dilutions, while 10 3 caused the lowest dilution with an 386 acceptable genotyping performance. For this reason, a 387 result comparable to 10 3 was set as genotyping limit for all 388 the four Real-Time PCRs, and all those results with a lower 389 quantity were not accepted. 390 As regards the clinical validation of the four genotyping 391 assays, the distribution of BKV genotypes was evaluated in The lowest limit of quantity of BKV-specific genotype, expressed in percentage, distinguishable from the background (aspecific amplification). In the case of no reported percentage, sporadic or no background amplification was observed 
